We are committed to protecting and safeguarding your personal data. We now meet the high standard for data privacy introduced by the new European data protection law known as the General Data Protection Regulation (GDPR) effective 25 May 2018.
You can review our policy at any time.
Our updated policy explains your rights under this new law, regarding how personal information is stored and processed. If you have any questions please don’t hesitate to contact us directly.
As always, thanks for being a part of our journey to make an impact on human wellbeing.
Trajan Scientific and Medical’s hemaPEN® microsampling technology has been developed with extensive consultation and evaluation by leading analytical laboratories, clinicians and healthcare professionals.
This month, Trajan presents an exclusive interview with researcher Dr Michele Protti of Pharmaco-Toxicological Analysis, Bologna, Italy, on the future of microsampling and the critical role hemaPEN can play when used in therapeutic drug monitoring for optimal therapy personalization.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.